News

EQS-News: Pentixapharm to Present First-in-Class Glycan-Dependent CD24 Antibody GT-008 for Solid Tumors at AACR 2025
EQS-News: Pentixapharm Holding AG / Key word (s): Conference/Scientific publication Pentixapharm to Present First-in-Class Glycan-Dependent CD24 Antibody GT-008 for Solid Tumors at AACR 2025 ...
PharmiWeb2d
Pentixapharm to Present First-in-Class Glycan-Dependent CD24 Antibody GT-008 for Solid Tumors at AACR 2025
Conference/Scientific publicationPentixapharm to Present First-in-Class Glycan-Dependent CD24 Antibody GT-008 for Solid Tumors at AACR 2025 25.04.2025 / 15:39 CET/CESTThe issuer is solely responsible ...
Modular protein adapter technology enables exosome-based precision drug delivery
A joint research team has developed a modular protein adapter technology that enables the stable attachment of various ...
News-Medical.Net3d
Chimeric RNA offers new clues for tailoring prostate cancer therapies
Prostate cancer has distinct genetic properties in different groups of men that can be targeted to improve patient outcomes, UVA Cancer Center researchers have discovered.
Taiwan News3d
BioNTech to Present Clinical and Preclinical Data Across mRNA and Next-Generation Immuno-Oncology Priority Programs at AACR 2025
Highlights of BioNTech’s oncology programs to be presented at AACR 2025: ...
DAAN Biotherapeutics and GC Cell agree on CAR-T, CAR-NK therapies
South Korea-based DAAN Biotherapeutics has entered a licensing agreement with GC Cell, granting the latter exclusive rights ...